Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen

AIDS

Volumn 24, Issue 17, 2010, Pages 2651-2656

  Charpentier, Charlotte ^a   Roquebert, Bénédicte ^a   Colin, Céline ^b   Taburet, Anne Marie ^c   Fagard, Catherine ^b   Katlama, Christine ^d   Molina, Jean Michel ^e   Jacomet, Christine ^f   Brun Vézinet, Françoise ^a   Chêne, Geneviève ^b   Yazdanpanah, Yazdan ^g   Descamps, Diane ^a  

^a BICHAT HOSPITAL   (France)

^b INSERM   (France)

^c BICÊTRE HOSPITAL   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f Hôpital de Clermont Ferrand   (France)

^g Tourcoing Hospital   (France)

Author keywords

darunavir; etravirine; HIV 1; raltegravir; resistance

Indexed keywords

DARUNAVIR PLUS RITONAVIR; ETRAVIRINE; RALTEGRAVIR;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG TREATMENT FAILURE; FISHER EXACT TEST; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANK SUM TEST; VIRUS LOAD;

ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PYRIDAZINES; RITONAVIR; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 78349304726     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833ed2a7     Document Type: Article

References (19)

1. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354.
2. Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, et al. Efficacy and safety of TMC125 (etravirine) in treat-ment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-con-trolled trial. Lancet 2007; 370:39-48.
3. Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, et al. Efficacy and safety of TMC125 (etravirine) in treat-ment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-con-trolled trial. Lancet 2007; 370:29-38.
4. Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, et al. Efficacyandsafety ofdarunavir-ritonaviratweek48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169-1178.
5. Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treat-ment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 2009; 49:1441-1449.
6. Johnson VA, Brun-Vezinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIVMed 2006; 14:125-130.
7. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, et al. Update of the drug resistance mutations in HIV-1: 2004. Top HIVMed2004; 12:119-124.
8. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009; 17:138-145.
9. Goldwirt L, Barrail-Tran A, Da Cruz M, Taburet AM, Furlan V. Quantification of raltegravir (MK0518) in human plasma by high-performance liquid chromatography with photodiode ar-ray detection. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878:456-460.
10. Caby F, Valin N, Marcelin AG, Schneider L, Andrade R, Guiguet M, et al. Raltegravir as functional monotherapy leads to vir-ological failure and drug resistance in highly treatment-experi-enced HIV-infected patients. Scand J Infect Dis 2010; 42:527-532.
11. Allavena C, Mounoury O, Rodallec A, André-Garnier E, Reli-quet V, Billaud E, et al. Raltegravir in HIV-1 ARV-experienced patients: high efficacy and absence of emergence of resistance mutations in low-grade virologic failures [abstract #PE7.9/15]. In: Program and Abstracts of the 12th European AIDS Confer-ence/EACS; 11-14 November 2009; Cologne, Germany.
12. Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, Andrade-Villanueva J, et al. Switch toa raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patientswithsuppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised con-trolled trials. Lancet 2010; 375:396-407.
13. Maguire M, Gartland M, Moore S, Hill A, Tisdale M, Harrigan R, et al. Absence ofzidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI2 andAVANTI 3 studies.AIDS 2000; 14:1195-1201.
14. Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, Moseley J, et al. Incidenceofresistanceinadouble-blindstudycomparing lopinavir/ritonavir plus stavudine and lamivudine tonelfinavir plus stavudine and lamivudine. J Infect Dis 2004; 189:5160.
15. De Meyer S, Lathouwers E, Dierynck I, De Paepe E, Van Baelen B, Vangeneugden T, et al. Characterization ofvirologic failure patients on darunavir/ritonavir in treatment-experienced pa-tients. AIDS 2009; 23:1829-1840.
16. Peeters M, Vingerhoets J, Tambuyzer L, Azijn H, Hill A, De Meyer S, et al. Etravirinelimitstheemergenceofdarunavirand other protease inhibitor resistance-associated mutations in the DUET trials. AIDS 2010; 24:921-924.
17. Miller M, Barnard R, Witmer M, Zhao J, Nguyen B-Y, Teppler H, et al. Short-term raltegravir monotherapy does not predispose patients to develop RAL resistance during subsequent combi-nation therapy: analysis ofsamples from protocol 004 [abstract #557]. In: Program and Abstracts of the 17th Conference on Retroviruses and Opportunistic Infections;16-19 February 2010; San Francisco, USA.
18. Ceccherini-Silberstein F, Van Baelen K, Armenia D, Trignetti M, Fabeni L, Rondelez E, et al. Novel HIV-1 integrase mutations, found as minority quasispecies in patients näive to integrase inhibitors, are associated with decreased susceptibility to in-tegrase inhibitors in vitro [abstract #876]. In: Program and Abstract of the 15th Conference on Retroviruses and Opportu-nistic Infections; 5-8 February 2008; Boston, USA.
19. da Silva D, Van Wesenbeeck L, Breilh D, Reigadas S, Anies G, Van Baelen K, et al. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virologi-cal failure on raltegravir-containing regimens. J Antimicrob Chemother 2010; 65:1262-1269.